PT-141
Melanocortin Receptor AgonistAlso known as: Bremelanotide, Vyleesi
FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Used off-label more broadly.
Filter by Goal
Aggregated data reflects community experience (16 total self-reports), not scientific consensus. This is not a clinical trial.
Outcome Breakdown
Based on 16 community reports
Reported Side Effects
Frequency among reporters who noted side effects
Common Forms
What the Scientific Literature Says
FDA-approved (bremelanotide/Vyleesi) for HSDD. Acts on melanocortin-4 receptors in the CNS. Clinical trials showed statistically significant improvement in sexual desire. Common side effects include nausea, flushing, and headache. Not approved for men but off-label use is reported.
External Discussions & Signal
BetaWhat the rest of the internet is saying about PT-141. Moderation-filtered, linked to the source — we don’t re-host content.
PT-141 nasal vs SC — anyone compared both routes directly?
Used SC for 3 months, switched to nasal for 2. Same dose equivalent (1.75mg SC / 10mg nasal). SC hits harder and faster but nausea is worse. Nasal is gentler with longer ramp. Posting in case others want the direct comparison.
Pulled via the Reddit API from subreddits matched to PT-141. Threads are ranked by a fact-check pass: well-documented → consistent with evidence → anecdotal. Unsupported-claim and sourcing posts are hidden by default. Click through to read on Reddit — we don’t re-host content.
Community Reports (1 displayed of 16)
Add yours3-month as-needed PT-141 use showed reliable pro-desire effects distinct from PDE5 inhibitor mechanism. Nausea is the main deterrent but improves with repeated use. High confidence due to clear temporal relationship between dose and effect.